A brave gran battling breast cancer for more than a decade is facing the heart-wrenching prospect of moving hundreds of miles to Scotland for access to a drug that could save her life. Beverley Angell ...

A grandma who has fought breast cancer for more than a decade may be forced to move to Scotland to access a lifesaving drug. Beverley Angell, 68, is having to consider moving 467 miles from London to ...

Beverley Angell, 68, is having to consider moving 467 miles from London to Scotland as the drug she needs - Enhurtu for HER2-low - is not available on the NHS in England. Privately it would cost ...

The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

Breast cancer drug Enhertu costs about £8,000 per session and is only available privately in England, but is offered on the ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

Enhertu gains EU approval for treating advanced breast cancer with low HER2 levels, marking a milestone for Daiichi Sankyo & ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to ...